Nav: Home

National Institute for Health and Care Excellence (NICE) issues new guidelines for COPD

December 11, 2018

REDWOOD CITY, California, December 10, 2018 - Pulmonx, a leader in interventional pulmonary device technology announced today that the National Institute for Health and Care Excellence (NICE) in the UK has expanded its guidance on the diagnosis and management of COPD to include which patients should be referred for evaluation for bronchoscopic lung volume reduction with Zephyr® Endobronchial Valves. The Zephyr Valves offer a minimally-invasive treatment option that has been shown to improve quality of life of emphysema patients by allowing them to breathe easier, be less short of breath, and be more active.

Key highlights in the NICE Report include:
  • "Strong" recommendation to assess patients with severe COPD for suitability for lung volume reduction procedures, including use of Zephyr Endobronchial Valves based on an in-depth analysis of patient outcomes data including improved lung function, quality of life, exercise capacity and survival.
  • "The criteria for referring patients for lung volume reduction assessment has been broadened, because treatment options now include endobronchial valves, a less invasive option which may benefit patients who were not candidates for more invasive surgical treatments. The broadening of criteria will lead to more referrals and improved access to treatment for patients."
  • Emphysema patients who have completed pulmonary rehabilitation, stopped smoking, have lung function of less than 50% of predicted, can walk at least 140 meters in 6 minutes (a standard exercise test), and suffer from breathlessness should be referred for evaluation for lung volume reduction procedures.
"NICE is respected globally for their in-depth evidence reviews and systematic approach to clinical guideline development. We appreciate NICE's thorough review of clinical data from multiple published Zephyr Valve randomized clinical trials 1, , , , , and believe this guidance will be a valuable resource for providers and payers seeking to improve patient care" said Glen French, President and Chief Executive Officer of Pulmonx.

The guideline committee further concluded that the endobronchial valve is likely to be cost effective compared with medical management.

"Patients with COPD suffer from breathlessness and that results in poor mobility and a lower quality of life. These patients need new, less invasive options and I am very pleased to see NICE recognize this need and recommend lung volume reduction with the Zephyr Valves," said Professor Pallav Shah of the Royal Brompton Hospital, London. "We hope to see other physicians refer more COPD patients to pulmonary specialists be evaluated for this less-invasive option."

More on the Zephyr Valves

Bronchoscopic lung volume reduction with the Zephyr Valve is a one-time procedure performed through a bronchoscope; it requires no cutting or incisions. During the procedure, an average of four tiny valves are placed in the airways to block off the diseased parts of the lungs. This allows trapped air to escape until the lobe is reduced in size. Reducing hyperinflation and preventing air from getting trapped in the diseased parts of the lung allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1 Patients treated report immediate relief and the ability to go back to doing everyday tasks with ease.

The Zephyr Valve was approved by the FDA in June 2018, through an expedited review because it "represents a breakthrough technology as the device offers bronchoscopic lung volume reduction without surgery and its associated risks. This device offers significant clinically meaningful advantages over the current standard of care and therefore, its availability is also in the best interest of patients." Since 2007, more than 15,000 patients have been treated with the Zephyr Valve worldwide. Zephyr Valve treatment is included in emphysema treatment guidelines such as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for Prevention, Diagnosis and Management of COPD, and is already recommended for routine use in the UK's National Institute for Health and Care Excellence (NICE) Interventional Procedures Guidance on Endobronchial Valves.

More about COPD and Emphysema

Chronic obstructive pulmonary disease (COPD) is a progressive, life-threatening lung disease that includes emphysema and chronic bronchitis. More than 65 million people suffer with COPD globally and it is estimated that 3.2 million deaths were caused by the disease in 2015 (5% of all deaths globally). Despite taking the best available medications, many COPD and emphysema patients suffer symptoms of hyperinflation, where air becomes trapped in the lungs and prevents fresh air from entering the lungs and thereby causing severe shortness of breath. Breathing becomes inefficient and patients must work very hard just to breathe - making normal activities, like walking, eating or even bathing, difficult. There are few treatment options for most patients with emphysema and there is no cure. Until now, the only other options for these patients were highly invasive treatments such as lung volume reduction surgery or lung transplantation.
-end-
About Pulmonx

Based in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx is the world leader in interventional pulmonology treatments for obstructive lung disease. For more information, visit http://www.MyLungsMyLife.com

Media Contact: Meghan Oreste, 617-823-1441, megoreste@gmail.com

NICE Guidelines: https://www.nice.org.uk/guidance/ng115/chapter/Recommendations#lung-surgery-and-lung-volume-reduction-procedures

1 Criner G. et al. Am J Respir Crit Care Med. 2018; 198 (9):1151-1164. 2 Kemp S et al. Am J Resp Crit Care Med. 2017; 196 (12): 1535-1543. 3 Valipour et al. Am J Respir Crit Care Med. 2016; 194(9): 1073-1082, and Data on file at Pulmonx. 4 Klooster K. et al. N Engl J Med. 2015; 373: 2325-2336, + Supplementary Appendix 5 Davey et al. Lancet 2015; 386(9998), 1066-1073. 6 Sciurba et al. N Engl J Med 2010; 363(13), 1233-1244. 7 Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet 2016; 388: 1459-1544.

Pulmonx

Related Emphysema Articles:

Emphysema treatment could be optimized using network modelling
A unique engineering perspective of emphysema progression in the lung suggests how mechanisms operating at the micromechanical scale could help to predict patient survival and quality of life following treatment -- according to new research published in PLOS Computational Biology.
Sugar element of keratan sulfate halts the progress of emphysema
Using a mouse model, scientists from the RIKEN-Max Planck Joint Research Center for Systems Chemical Biology and a number of other institutes have identified a sugar molecule that reduced the inflammatory response and progress of emphysema, a common component of chronic obstructive pulmonary disease (COPD).
New targeted gene therapy could lead to improved treatment for emphysema
Researchers have developed a new strategy using lung-targeted gene therapy that may lead to improved treatments for inherited diseases including emphysema.
Tiny coils improve quality of life for patients with severe emphysema
Results from a large international trial were presented by researchers from the University of Pittsburgh School of Medicine at the American Thoracic Society International Meeting in San Francisco.
From genes to latrines: Vikings and their worms provide clues to emphysema
In a paper published today in Nature: Scientific Reports a group of researchers led by LSTM have found that the key to an inherited deficiency, predisposing people to emphysema and other lung conditions, could lie in their Viking roots.
Treatment for severe emphysema improves exercise capacity
In preliminary research for patients with severe emphysema, a minimally invasive intervention involving the implantation of coils in the lungs with an endoscope resulted in improved exercise capacity at six months, although with high short-term costs, according to a study in the Jan.
Nanoparticulate carbon black particles tiny culprits that start emphysema
When pathologists perform autopsies on smokers who died with severe emphysema, they find that lungs are black in appearance.
Imaging could improve treatment of people with COPD
Magnetic resonance imaging and computed tomography provide important information on the symptoms and exercise capabilities of people with mild-to-moderate chronic obstructive pulmonary disease, according to a new study.
Study shows treatment for genetically caused emphysema is effective
A landmark clinical study in the Lancet provides convincing evidence that a frequently overlooked therapy for genetically-caused emphysema is effective and slows the progression of lung disease.
Regular aspirin use may slow progression of early emphysema
Regular use of aspirin may help slow the progression of early emphysema, according to new research presented at the 2015 American Thoracic Society International Conference.

Related Emphysema Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Changing The World
What does it take to change the world for the better? This hour, TED speakers explore ideas on activism—what motivates it, why it matters, and how each of us can make a difference. Guests include civil rights activist Ruby Sales, labor leader and civil rights activist Dolores Huerta, author Jeremy Heimans, "craftivist" Sarah Corbett, and designer and futurist Angela Oguntala.
Now Playing: Science for the People

#520 A Closer Look at Objectivism
This week we broach the topic of Objectivism. We'll be speaking with Keith Lockitch, senior fellow at the Ayn Rand Institute, about the philosophy of Objectivism as it's taught through Ayn Rand's writings. Then we'll speak with Denise Cummins, cognitive scientist, author and fellow at the Association for Psychological Science, about the impact of Objectivist ideology on society. Related links: This is what happens when you take Ayn Rand seriously Another Critic Who Doesn’t Care What Rand Thought or Why She Thought It, Only That She’s Wrong Quote is from "A Companion to Ayn Rand"